GSK to Acquire Nuvalent for $10.6 Billion in Major Oncology Push
NUVL sits 73% above its 52-week low of $71.13 on elevated volume (1.8× avg).
Summary
GSK has agreed to acquire Nuvalent, a cancer drug developer, for $10.6 billion. This represents a substantial premium over Nuvalent's current market valuation. The acquisition is GSK's largest deal in over a decade, signaling a significant strategic shift to bolster its oncology focus. For Nuvalent shareholders, this provides a clear and highly lucrative exit, validating the company's pipeline, which recently saw its New Drug Application for neladalkib granted FDA Priority Review. The deal will be subject to regulatory approvals and a shareholder vote.
At the time of this announcement, NUVL was trading at $122.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $71.13 to $113.02. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.